Innovus Pharma enrols first subject in musclin trial

11th December 2018 (Last Updated December 11th, 2018 00:00)

Innovus Pharmaceuticals has enrolled the first subject in a clinical trial that is designed to assess the effect and tolerance of Musclin on muscle health.

Innovus Pharmaceuticals has enrolled the first subject in a clinical trial designed to assess the effect and tolerance of musclin on muscle health.

The open-label, uncontrolled, ascending dose trial aims to include up to 20 healthy adults and is currently being conducted at a single site in the US.

Musclin is a dietary supplement that includes thymol and bioperine. It supports muscle mass, muscle recovery time, and improve endurance levels in adults.

Subjects will receive a daily dose of two musclin capsules for 30 days as part of the trial.

"This study represents part of Innovus Pharma’s strategy to leverage cutting-edge technologies that have been developed by pioneers in the field of muscle health."

The completion of the 30-day period means the subjects will receive four capsules of musclin for an additional 30 days.

The primary objective of the trial is to evaluate the tolerance of musclin, while additional aims comprise self-reported changes in energy and stamina levels.

Innovus Pharma president and CEO Bassam Damaj said: “This study represents part of Innovus Pharma’s strategy to leverage cutting-edge technologies that have been developed by pioneers in the field of muscle health and introduce clinically-tested and proven products to consumers.

“As a result of its unique mechanism of action on muscle fibres, we believe musclin is one of the few products targeting the muscle fibres specifically and not the whole body protein synthesis pathways.

“We are hoping results from this study and potentially others to come will help to support individuals who want to maintain optimal muscle health as they age or suffer from muscle weaknesses.”

The trial plans to complete and publish results from the trial in the first half of next year.